Hälsa & åldrande

Researchers found that combining two plasma biomarkers—p-tau217 and eMTBR-tau243—significantly improves Alzheimer's diagnosis and predicts cognitive decline in patients with memory problems. The combination test could reshape clinical trial recruitment and help insurers and healthcare systems identify at-risk patients sooner, potentially unlocking demand for emerging disease-modifying treatments.EN

Researchers have pinpointed exactly where amyloid fibrils—the toxic protein clumps that destroy brain cells—spawn new copies of themselves. By removing these structural defects, they dramatically slowed the process. The finding could reshape drug development strategies for neurodegenerative diseases affecting millions worldwide.EN

Swedish researchers found that six blood biomarkers can identify older adults who will decline rapidly in both thinking and movement—a dual decline that signals fast-track progression to dementia. The finding suggests simple blood tests could enable early intervention and reshape how clinicians screen aging populations for disease risk.EN

Latinamerikansk studie visar att strukturerad livsstilsintervention kan göra skillnad för kognitiv hälsa hos äldre. LatAm-FINGERS-studien omfattade över 2 000 deltagare mellan 60 och 77 år i elva länder och jämförde en intensiv, övervakad livsstilsprogram med standard hälsoråd. Det strukturerade programmet innefattade träning, kostråd, kognitiv träning och socialt engagemang anpassat för latinamerikansk kultur. Interventionen pågick under två år, och forskarna mätte förändringar i kognitiv funktion samt hur väl programmet fungerade i praktiken. Studien utförs av demensforskare vid Fleni i Buenos Aires tillsammans med institutioner i flera latinamerikanska länder och USA. För äldreomsorg och demenspreventionsverksamhet är fyndet relevant: det visar att målriktad livsstilsintervention är genomförbar i befolkningar med höga demensrisker. Resultaten kan påverka vilka förebyggande program som prioriteras framöver.

Amyloid-PET blir ett allt viktigare diagnostiskt verktyg för att skilja Alzheimers sjukdom från andra kognitiva nedsättningar och för att välja kandidater till nya läkemedel. En ny samanalys från 49 227 patienter i 53 studier etablerar enhetliga, datadrivna gränsvärden för hur bilderna ska tolkas — ett problem som hittills varierat mellan kliniker och forskargrupper. Forskarna testade två metoder: en enkel gränsvärdesmodell för klassificering som positiv eller negativ, samt en tvåstegsmodell som identifierar en osäkerhetszon där resultatet är mindre säkert. Analyserna baserades på så kallad Centiloid-skala, en standardiserad måttenhet för amyloidmängd som möjliggör jämförbara läsningar oavsett vilket radioaktivt spårämne som används. Resultatet ger kliniker och läkemedelsutvecklare ett gemensamt språk för amyloid-PET-diagnostik. Det förkortar tiden från undersökning till terapibeslut och minskar risken för feldiagnoser — kritiskt när nya alzheimermediciner kräver biologisk bekräftelse av amyloidpatolgi.

A new analysis warns that combining diverse Alzheimer's cases in research studies could obscure important biological differences that affect treatment outcomes. The finding challenges how the field designs trials and pools data, potentially explaining why some drugs fail and suggesting pharmaceutical and health policy decision-makers need more precise patient categorization strategies.EN

Italian medical authorities have issued the first national consensus guidelines endorsing a simple blood test for Alzheimer's disease that matches the accuracy of expensive imaging and invasive procedures. The recommendation could accelerate dementia screening across Europe and reshape diagnostics for the continent's aging population.EN

Researchers have discovered how amyloid-beta, one of Alzheimer's hallmark proteins, acts as a chemical catalyst to accelerate the toxic aggregation of tau protein in the brain. The finding could reshape drug development strategies, suggesting companies should target the interaction between the two proteins rather than attacking them separately.EN

A refined blood biomarker called brain-derived pTau217 outperforms existing tests by filtering out noise from kidney disease, which can skew results. The finding could accelerate Alzheimer's diagnosis in millions of patients with concurrent kidney problems—a common scenario in aging populations—and open new markets for diagnostic companies.EN

Researchers have developed a simple blood test that can forecast when cognitively normal people will develop Alzheimer's symptoms—with a margin of error of just 3-4 years. The advance could transform clinical trial recruitment and eventually enable preventive medicine, while cutting costs by replacing expensive brain imaging with a single plasma biomarker test.EN

Researchers have developed small molecule compounds that prevent amyloid-beta proteins from aggregating—a hallmark of Alzheimer's disease. The finding could accelerate development of disease-modifying treatments for a condition affecting millions globally, potentially opening a significant market opportunity for pharmaceutical companies pursuing neurodegeneration therapeutics.EN

Researchers analyzed multiple patient cohorts to pinpoint the metabolic mechanisms underlying frailty—a costly condition affecting millions of older adults. The findings could guide development of therapies to prevent disability and reduce healthcare spending on age-related decline.EN

Dementia is becoming less common among people in their 80s, according to new research tracking three generations born 30 years apart. The finding—which contradicts predictions of rising dementia cases—has major implications for healthcare systems, insurance companies, and retirement planning, suggesting that improved education and cardiovascular health may be shifting the trajectory of cognitive decline.EN

Researchers identified how a molecular chaperone called BRICHOS blocks the buildup of amyloid-beta, a protein linked to Alzheimer's disease. The finding could accelerate development of treatments that prevent neurodegeneration by stopping disease progression at its molecular roots—a shift that could reshape how drugmakers approach brain disease.EN

Nurses working in municipal home healthcare face significant barriers to implementing basic safety practices, according to new research from Scandinavia. The findings highlight gaps in how care systems are structured—a concern for health administrators managing liability, staff burnout, and patient outcomes.EN

Researchers found that physical frailty measurements can predict who will develop cancer, potentially years in advance. The discovery could reshape cancer screening strategies and help health systems allocate prevention resources more effectively by targeting vulnerable populations before tumors emerge.EN

A longitudinal study published in Brain, Behavior, & Immunity - Health examines how chronic physiological stress—measured through allostatic load—correlates with Alzheimer's biomarkers and cognitive decline. The findings could reshape how clinicians identify high-risk patients and inform pharmaceutical and diagnostic company strategies in dementia care.EN

A new study reveals that disclosing amyloid-PET scan results to people with memory concerns causes measurable psychological symptoms—a finding that could reshape how doctors communicate disease risk and inform the rollout of new Alzheimer's screening and prevention programs.EN

An analysis of existing research identifies which programs actually help informal caregivers—typically adult children caring for aging parents—reduce stress and health problems. The findings matter for employers and insurers weighing whether to fund caregiver support programs, which affect workforce productivity and healthcare costs.EN

Researchers have identified a quick, non-verbal test that could serve as an early warning system for cognitive aging. The finding could help clinicians and insurers identify high-risk patients sooner, potentially enabling earlier interventions before significant mental decline occurs.EN

A European task force has released the first coordinated set of recommendations for how memory clinics should prevent dementia rather than simply treating it after diagnosis. The guidance matters for health systems and insurers facing rising dementia costs, offering a clear framework to shift toward early intervention strategies.EN

Semaglutide, a GLP-1 receptor agonist already used for diabetes and obesity, slowed cognitive decline in early-stage Alzheimer's patients across two major Phase 3 trials. The finding could open a new therapeutic avenue for the neurodegenerative disease and reshape treatment protocols if results hold—significant news for pharma, insurers, and healthcare systems preparing for aging populations.EN

A major Swedish study of half a million people found that cumulative use of anticholinergic drugs—used to treat everything from incontinence to depression—significantly increases cardiovascular event risk. The finding could reshape prescribing practices and force pharmaceutical companies and healthcare systems to reassess safety profiles of widely used medications.EN

A new health technology assessment finds that an AI tool designed to predict which mild cognitive impairment patients will develop dementia actually reduces quality-adjusted life years and increases costs when no disease-modifying treatments are available. The finding suggests deploying such prediction tools prematurely could harm patients psychologically while draining healthcare budgets.EN

A three-year study shows that frailty—a measure of biological aging—independently predicts how quickly Parkinson's disease worsens and whether patients develop motor complications. The finding could reshape treatment strategies and help clinicians identify high-risk patients earlier, potentially opening new avenues for intervention before irreversible decline occurs.EN